The effect of folate deficiency on the cytotoxic and mutagenic responses to ethyl methanesulfonate in human lymphoblastoid cell lines that differ in p53 status.
Folic acid deficiency acts synergistically with alkylating agents to increase genetic damage at the HPRT locus in Chinese hamster ovary cells in vitro and in rat splenocytes in vivo. The present studies extend these observations to human cells and, in addition, investigate the role of p53 activity on mutation induction. The human lymphoblastoid cell lines TK6 and WTK1 are derived from the same parental cell line (WI-L2), but WTK1 expresses mutant p53. Treatment of folate-replete or deficient WTK1 and TK6 cells with increasing concentrations (0-50microg/ml) of ethyl methanesulfonate (EMS) resulted in significantly different HPRT mutation dose-response relationships (P<0.01), indicating that folate deficiency increased the EMS-induced mutant frequency in both cell lines, but with a greater effect in TK6 cells. Molecular analyses of 152 mutations showed that the predominant mutation (65%) in both cell types grown in the presence or absence of folic acid was a G>A transition on the non-transcribed strand. These transitions were mainly at non-CpG sites, particularly when these bases were flanked 3' by a purine or on both sides by G:C base pairs. A smaller number of G>A transitions occurred on the transcribed strand (C>T=14%), resulting in 79% total G:C>A:T transitions. There were more genomic deletions in folate-deficient (15%) as compared to replete cells (4%) of both cell types. Mutations that altered RNA splicing were common in both cell types and under both folate conditions, representing 33% of the total mutations. These studies indicate that cells expressing p53 activity exhibit a higher rate of mutation induction but are more sensitive to the toxic effects of alkylating agents than those lacking p53 activity. Folate deficiency tends to reduce toxicity but increase mutation induction after EMS treatment. The p53 gene product did not have a major influence on the molecular spectrum after treatment with EMS, while folate deficiency increased the frequency of deletions in both cell types.
Branda
R F
RF
Department of Medicine and The Vermont Cancer Center, University of Vermont, Burlington, VT 05405, USA. rbranda@zoo.uvm.edu
O'Neill
J P
JP
Brooks
E M
EM
Trombley
L M
LM
Nicklas
J A
JA
D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D001483:Base Sequence; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D004252:DNA Mutational Analysis; D004305:Dose-Response Relationship, Drug; D005020:Ethyl Methanesulfonate / Q000494:pharmacology*; D005492:Folic Acid / Q000494:pharmacology*; D006801:Humans; D008969:Molecular Sequence Data; D016296:Mutagenesis / Q000187:drug effects*; D009153:Mutagens / Q000494:pharmacology; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000494:pharmacology*
D018906:Antineoplastic Agents, Alkylating; D009153:Mutagens; D016159:Tumor Suppressor Protein p53; D005492:Folic Acid; D005020:Ethyl Methanesulfonate